Integration of genetic and clinical risk factors improves prognostication in relapsed childhood B-cell precursor acute lymphoblastic leukemia.
about
Acute lymphoblastic leukaemia cells produce large extracellular vesicles containing organelles and an active cytoskeletonTumor suppressors BTG1 and IKZF1 cooperate during mouse leukemia development and increase relapse risk in B-cell precursor acute lymphoblastic leukemia patients.Stability of patient-specific features of altered DNA replication timing in xenografts of primary human acute lymphoblastic leukemia.Clinical significance of recurrent copy number aberrations in B-lineage acute lymphoblastic leukaemia without recurrent fusion genes across age cohorts.Genomic characterization of paediatric acute lymphoblastic leukaemia: an opportunity for precision medicine therapeutics.Suppressors and activators of JAK-STAT signaling at diagnosis and relapse of acute lymphoblastic leukemia in Down syndrome.TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens.A risk score including microdeletions improves relapse prediction for standard and medium risk precursor B-cell acute lymphoblastic leukaemia in children.TP53 Germline Variations Influence the Predisposition and Prognosis of B-Cell Acute Lymphoblastic Leukemia in Children.Genotype-Specific Minimal Residual Disease Interpretation Improves Stratification in Pediatric Acute Lymphoblastic Leukemia.RAS pathway mutations as a predictive biomarker for treatment adaptation in pediatric B-cell precursor acute lymphoblastic leukemia.Mutational status of NRAS, KRAS, and PTPN11 genes is associated with genetic/cytogenetic features in children with B-precursor acute lymphoblastic leukemia.Copy number profiling of adult relapsed B-cell precursor acute lymphoblastic leukemia reveals potential leukemia progression mechanisms.New targeted therapies for relapsed pediatric acute lymphoblastic leukemia.
P2860
Q30843368-6BCD55C5-1FEE-4542-AEF3-E376229BF39FQ33573735-96EC6129-4D39-43AC-9607-5728048142A1Q38691997-031F8866-843F-4E7E-92E9-65C18A497AC0Q38821571-83045BAE-BD4D-4CBA-ADB6-7652EEDA00D2Q39041475-ED479101-B1F4-47B7-B867-71E3F64A03DBQ45233800-D227F0AC-66EA-4973-8D08-3A0640365476Q46317683-B47308C4-8F4A-4BEA-A134-6C95D523D979Q47203054-0B0236C2-2827-4CAD-B93F-6B09AD9CE4C0Q47564553-28AA53A1-DE3D-40CC-828E-AC83BE6A0C48Q47607855-1930E813-F5F0-4834-91F5-933233906E29Q47875530-6C934AE2-4E44-4296-9985-6E222F5CCBF7Q47884832-F1949097-917A-4DFE-8C25-0264CA34AB9FQ48323019-EDFE9FE7-E64C-4085-A865-AF972D507630Q51839566-53AB91CF-8AA1-42EE-8113-CB9F45CB413B
P2860
Integration of genetic and clinical risk factors improves prognostication in relapsed childhood B-cell precursor acute lymphoblastic leukemia.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 26 May 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Integration of genetic and cli ...... acute lymphoblastic leukemia.
@en
Integration of genetic and cli ...... acute lymphoblastic leukemia.
@nl
type
label
Integration of genetic and cli ...... acute lymphoblastic leukemia.
@en
Integration of genetic and cli ...... acute lymphoblastic leukemia.
@nl
prefLabel
Integration of genetic and cli ...... acute lymphoblastic leukemia.
@en
Integration of genetic and cli ...... acute lymphoblastic leukemia.
@nl
P2093
P2860
P50
P1433
P1476
Integration of genetic and cli ...... acute lymphoblastic leukemia.
@en
P2093
Alysia Davies
Amir Enshaei
Amy Erhorn
Catriona A Parker
Claire Schwab
Edwin Sonneveld
Elizabeth Matheson
Jiangyan Yu
Julie A E Irving
Lynne Minto
P2860
P304
P356
10.1182/BLOOD-2016-03-704973
P407
P577
2016-05-26T00:00:00Z